Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03365479 Recruiting - Clinical trials for Pulmonary Hypertension

Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Primary objective • To evaluate the effect of rapid inhalation of 2.5μgiloprost using the Breelib nebulizer on pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension Secondary objectives - To evaluate the effect of rapid iloprost inhalation using the Breelib nebulizer on mean pulmonary arterial pressure (mPAP), cardiac output (CO), cardiac index (CI), systemic blood pressure, arterial oxygen saturation, heart rate, and pulmonary arterial wedge pressure (PAWP). - To evaluate the safety and tolerability of the rapid iloprost inhalation using the Breelib nebulizer.

NCT ID: NCT03364244 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Revavtio Special Investigation for Long-term Use in Pediatric Patients

Start date: November 30, 2017
Phase: N/A
Study type: Observational

Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice

NCT ID: NCT03360669 Recruiting - Hypertension Clinical Trials

Comparison of Blood Pressure Measurement With an Omron HEM-907 Device in a Clinical Setting and a Research Setting

OMRONHEM-907
Start date: November 27, 2017
Phase: N/A
Study type: Interventional

Automated office blood pressure (AOBP) devices are recommended for high blood pressure diagnosis. One of those devices is the Omron HEM-907 (Omron Healthcare). It is currently not known if blood pressure measurements performed with this device in a clinical setting are equivalent to those made in a research setting. Therefore, this randomized-controlled trial was designed. It aims to compare the blood pressure measurements performed in a clinical and a research setting. Seventy patients will be included and randomized to a clinical/research or research/clinical sequence.

NCT ID: NCT03354897 Recruiting - Hypertension Clinical Trials

Clinical Study of UMOD MKCC2 Interaction on Salt-sensitivity in Hypertension

UMOD
Start date: April 5, 2017
Phase: Phase 4
Study type: Interventional

The hypothesis is based on UMOD rs13333226 genotype, there are two strata of hypertensive patients. The High-UMOD group (AA genotype) has increased UMOD excretion, greater salt sensitivity, HTN, normal eGFR and greater BP response to loop diuretics like furosemide. The Low-UMOD group (G allele) has decreased UMOD excretion, salt resistance, increased eGFR, increased proximal tubular reabsorption of Na (possibly related to increased GFR), a poor BP response to loop diuretics, and possibly diminished function of NKCC2. The High-UMOD strata will have decreased delivery of Na+ to the distal tubule and collecting duct because NKCC2 function is normal and the study hypothesis is that the participants will be more responsive to loop diuretics. In contrast, the Low-UMOD group (G allele) will not show a similar response to loop diuretics. This may be related either to lower Na delivery to the TAL, because of increased proximal tubular reabsorption of Na+, or a suppressed function of NKCC2. The population distribution of the High-UMOD group (AA) is 67%. Our overall objective is to test the hypothesis that hypertensive subjects with uncontrolled HTN open possessing the AA genotype of rs13333226 will be better responders to loop diuretics compared to those possessing the G allele.

NCT ID: NCT03349918 Recruiting - Hypertension Clinical Trials

PERsonal ContExtual Precision healTh

PERCEPT
Start date: November 6, 2017
Phase: N/A
Study type: Interventional

The exponential growth of physiological, behavioral and environmental data generated through consumer mobile health (mHealth) devices and Internet of Things (IoT) technology provide unprecedented sources of personalized and contextual health information. If linked to clinical health data from the Electronic Health Record (EHR), these data can provide dynamic and individualized views of patient health states and trajectories that can greatly inform clinical care and health-related research. The investigators propose to advance precision health through the development and evaluation of a mobile application and data platform that collects, harmonizes and integrates mHealth and environmental data from patients' daily lives with their clinical histories and electronic health record data. The investigators propose a participatory design approach to implement and evaluate a precision health platform through the study and modeling of hypertension (HTN) and depression in patient communities of UC Davis (UCD) and UC San Francisco (UCSF). These chronic diseases have high prevalence across geography, socioeconomic status, and race/ethnicity, and have significant economic, societal and personal costs. They are considerably challenging to manage due to difficulties in acquiring high-quality and consistent data from patients outside of their clinical care appointments that is so needed for a full view of the patient's disease state. Despite a broad array of self-monitoring devices and consumer applications, mHealth data are not getting into the clinical care process, and patients do not regularly monitor their own health states, particularly during periods of medication change, when frequent assessments are especially important. The investigators propose to conduct a 6-month single arm feasibility study of 200 ambulatory men and women (100 each at UCSF and UCD) with either hypertension or depression to implement an open, web-accessible, standards driven and patient-centric data platform for the integration of patient-reported and clinical data.

NCT ID: NCT03349775 Recruiting - Obesity Clinical Trials

Cardiometabolic Disease and Pulmonary Hypertension

Start date: November 27, 2017
Phase: N/A
Study type: Interventional

This study will investigate if metformin can help people with obesity and high pressures inside their lung blood vessels. Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, but metformin is not approved by the FDA to treat pulmonary hypertension. This study will examine whether Metformin will improve the high pressure inside lung blood vessels in people who are obese. The study will help understand the effect of metformin on pressures inside lung blood vessels.

NCT ID: NCT03349164 Recruiting - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region

NCTEPHR
Start date: January 1, 2017
Phase: N/A
Study type: Observational

There will be assessment of patients after acute pulmonary embolism for the development of CTEPH

NCT ID: NCT03348280 Recruiting - Hypertension Clinical Trials

Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics

VDIM
Start date: September 1, 2017
Phase: N/A
Study type: Observational

This trial will evaluate whether a particular type of circulating white blood cell, monocytes, from type 2 diabetics with high blood pressure and vitamin D deficiency vs. sufficiency will induce hormones that increase blood pressure.

NCT ID: NCT03345212 Recruiting - Clinical trials for Pulmonary Hypertension

A Randomized Controlled Multicenter Trial of Exercise Training in Pulmonary Hypertension in European Countries

EU-TRAIN-01
Start date: February 2016
Phase: N/A
Study type: Interventional

Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of life and right ventricular function. The disease is characterized by an increase of pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency. Despite optimized combination-medical therapy most patients remain symptomatic, have reduced exercise capacity, quality of life and reduced survival rates, with an annual mortality rate of approximately 5 -15 % or even higher. Previous training studies have suggested that exercise training as add-on to medical treatment is highly effective improving exercise capacity, quality of life and symptoms. The current guidelines recommend exercise training only in specialized centres including both PH and rehabilitation specialists who are experienced in exercise training of severely compromised patients. A specialized PH-training program has been performed in Heidelberg since 2003 including >1200 patients with various forms of chronic PH. The exercise training program is performed in a special setting with an in-hospital start of the rehabilitation program. It is characterized by a low-dose closely supervised exercise training in small groups with additional psychological support and mental training. This training program for patients with PH will be implemented in European centers to add exercise training to the existing PH therapies. The effect of the training on physical exercise capacity will be assessed by 6-minute walking distance (6-MWD). Further clinical parameters will be assessed to evaluate the effect on exercise capacity, quality of life and symptoms. The aim of this study is to guide European PH-centers to become specialized centers for training in PH. 126 patients will be included, who either receive exercise training or continue their daily sedentary life style (1:1 randomization) for 15 weeks. As inpatient settings are not available in all healthcare systems the training program will be adapted from the specific training program for PH patients developed in Heidelberg to a procedure, which is feasible in the local participating centres. Another objective of this study is to assess if the particular adopted training program specified for each participating centre and country is still safe and effective.

NCT ID: NCT03332043 Recruiting - Clinical trials for Cardiovascular Diseases

HIRREM for Pre-Hypertension

Start date: January 2018
Phase: N/A
Study type: Interventional

This randomized, controlled clinical pilot trial will evaluate the effects associated with in-office use of closed-loop, acoustic stimulation neurotechnology (High-resolution, relational, resonance-based, electroencephalic mirroring; HIRREM), compared with acoustic stimulation not linked to brainwaves (ambient nature sounds), for participants with pre-hypertension. Data collection will occur at baseline, and at intervals after completion of the intervention. Outcomes include blood pressure, measures of autonomic cardiovascular regulation, behavioral symptom outcomes, quality of life, alcohol use, and functional performance measures. The primary outcome will be change in blood pressure from baseline to 4-6 weeks after intervention.